Skip to main content
Top
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity

Authors: Elizabeth C Martin, Lyndsay V Rhodes, Steven Elliott, Adrienne E Krebs, Kenneth P Nephew, Erik K Flemington, Bridgette M Collins-Burow, Matthew E Burow

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

The AKT/mammalian target of rapamycin (mTOR) signaling pathway is regulated by 17α-estradiol (E2) signaling and mediates E2-induced proliferation and progesterone receptor (PgR) expression in breast cancer.

Methods and results

Here we use deep sequencing analysis of previously published data from The Cancer Genome Atlas to demonstrate that expression of a key component of mTOR signaling, rapamycin-insensitive companion of mTOR (Rictor), positively correlated with an estrogen receptor-α positive (ERα+) breast tumor signature. Through increased microRNA-155 (miR-155) expression in the ERα+ breast cancer cells we demonstrate repression of Rictor enhanced activation of mTOR complex 1 (mTORC1) signaling with both qPCR and western blot. miR-155-mediated mTOR signaling resulted in deregulated ERα signaling both in cultured cells in vitro and in xenografts in vivo in addition to repressed PgR expression and activity. Furthermore we observed that miR-155 enhanced mTORC1 signaling (observed through western blot for increased phosphorylation on mTOR S2448) and induced inhibition of mTORC2 signaling (evident through repressed Rictor and tuberous sclerosis 1 (TSC1) gene expression). mTORC1 induced deregulation of E2 signaling was confirmed using qPCR and the mTORC1-specific inhibitor RAD001. Co-treatment of MCF7 breast cancer cells stably overexpressing miR-155 with RAD001 and E2 restored E2-induced PgR gene expression. RAD001 treatment of SCID/CB17 mice inhibited E2-induced tumorigenesis of the MCF7 miR-155 overexpressing cell line. Finally we demonstrated a strong positive correlation between Rictor and PgR expression and a negative correlation with Raptor expression in Luminal B breast cancer samples, a breast cancer histological subtype known for having an altered ERα-signaling pathway.

Conclusions

miRNA mediated alterations in mTOR and ERα signaling establishes a new mechanism for altered estrogen responses independent of growth factor stimulation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dunlop EA, Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cellular signalling. 2009, 21: 827-835. 10.1016/j.cellsig.2009.01.012CrossRefPubMed Dunlop EA, Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cellular signalling. 2009, 21: 827-835. 10.1016/j.cellsig.2009.01.012CrossRefPubMed
2.
go back to reference Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N: mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010, 328: 1172-1176. 10.1126/science.1187532PubMedCentralCrossRefPubMed Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N: mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010, 328: 1172-1176. 10.1126/science.1187532PubMedCentralCrossRefPubMed
3.
go back to reference Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer research. 2011, 71: 3246-3256. 10.1158/0008-5472.CAN-10-4058PubMedCentralCrossRefPubMed Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer research. 2011, 71: 3246-3256. 10.1158/0008-5472.CAN-10-4058PubMedCentralCrossRefPubMed
4.
go back to reference Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes & development. 2004, 18: 1926-1945. 10.1101/gad.1212704CrossRef Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes & development. 2004, 18: 1926-1945. 10.1101/gad.1212704CrossRef
5.
go back to reference Kim J, Kundu M, Viollet B, Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature cell biology. 2011, 13: 132-141. 10.1038/ncb2152PubMedCentralCrossRefPubMed Kim J, Kundu M, Viollet B, Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature cell biology. 2011, 13: 132-141. 10.1038/ncb2152PubMedCentralCrossRefPubMed
6.
go back to reference Sengupta S, Peterson TR, Sabatini DM: Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Molecular cell. 2010, 40: 310-322. 10.1016/j.molcel.2010.09.026PubMedCentralCrossRefPubMed Sengupta S, Peterson TR, Sabatini DM: Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Molecular cell. 2010, 40: 310-322. 10.1016/j.molcel.2010.09.026PubMedCentralCrossRefPubMed
7.
go back to reference Huang J, Manning BD: A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society transactions. 2009, 37: 217-222. 10.1042/BST0370217PubMedCentralCrossRefPubMed Huang J, Manning BD: A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society transactions. 2009, 37: 217-222. 10.1042/BST0370217PubMedCentralCrossRefPubMed
8.
go back to reference Huang J, Dibble CC, Matsuzaki M, Manning BD: The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and cellular biology. 2008, 28: 4104-4115. 10.1128/MCB.00289-08PubMedCentralCrossRefPubMed Huang J, Dibble CC, Matsuzaki M, Manning BD: The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and cellular biology. 2008, 28: 4104-4115. 10.1128/MCB.00289-08PubMedCentralCrossRefPubMed
9.
go back to reference Huang J, Wu S, Wu CL, Manning BD: Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer research. 2009, 69: 6107-6114.PubMedCentralCrossRefPubMed Huang J, Wu S, Wu CL, Manning BD: Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer research. 2009, 69: 6107-6114.PubMedCentralCrossRefPubMed
10.
go back to reference Julien LA, Carriere A, Moreau J, Roux PP: mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and cellular biology. 2010, 30: 908-921. 10.1128/MCB.00601-09PubMedCentralCrossRefPubMed Julien LA, Carriere A, Moreau J, Roux PP: mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and cellular biology. 2010, 30: 908-921. 10.1128/MCB.00601-09PubMedCentralCrossRefPubMed
11.
go back to reference Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. The Journal of clinical investigation. 2008, 118: 3065-3074.PubMedCentralPubMed Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. The Journal of clinical investigation. 2008, 118: 3065-3074.PubMedCentralPubMed
12.
go back to reference Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102: 8204-8209. 10.1073/pnas.0502857102PubMedCentralCrossRefPubMed Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102: 8204-8209. 10.1073/pnas.0502857102PubMedCentralCrossRefPubMed
13.
go back to reference Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005, 23: 7721-7735. 10.1200/JCO.2005.09.004CrossRef Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005, 23: 7721-7735. 10.1200/JCO.2005.09.004CrossRef
14.
go back to reference Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular endocrinology. 2003, 17: 575-588. 10.1210/me.2002-0318CrossRefPubMed Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular endocrinology. 2003, 17: 575-588. 10.1210/me.2002-0318CrossRefPubMed
15.
go back to reference Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D: The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Molecular endocrinology. 2011, 25: 516-528. 10.1210/me.2010-0373PubMedCentralCrossRefPubMed Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D: The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Molecular endocrinology. 2011, 25: 516-528. 10.1210/me.2010-0373PubMedCentralCrossRefPubMed
16.
go back to reference Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005, 11: 5319-5328. 10.1158/1078-0432.CCR-04-2402CrossRef Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005, 11: 5319-5328. 10.1158/1078-0432.CCR-04-2402CrossRef
17.
go back to reference Chang SB, Miron P, Miron A, Iglehart JD: Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. The Journal of surgical research. 2007, 138: 37-44. 10.1016/j.jss.2006.07.003CrossRefPubMed Chang SB, Miron P, Miron A, Iglehart JD: Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. The Journal of surgical research. 2007, 138: 37-44. 10.1016/j.jss.2006.07.003CrossRefPubMed
18.
go back to reference Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D, Zhu J: The UCSC Cancer Genomics Browser: update 2013. Nucleic acids research. 2013, 41: D949-954. 10.1093/nar/gks1008PubMedCentralCrossRefPubMed Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D, Zhu J: The UCSC Cancer Genomics Browser: update 2013. Nucleic acids research. 2013, 41: D949-954. 10.1093/nar/gks1008PubMedCentralCrossRefPubMed
19.
go back to reference Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J: The UCSC Cancer Genomics Browser: update 2011. Nucleic acids research. 2011, 39: D951-959. 10.1093/nar/gkq1113PubMedCentralCrossRefPubMed Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J: The UCSC Cancer Genomics Browser: update 2011. Nucleic acids research. 2011, 39: D951-959. 10.1093/nar/gkq1113PubMedCentralCrossRefPubMed
20.
go back to reference Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM: Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010, 26: i237-245. 10.1093/bioinformatics/btq182PubMedCentralCrossRefPubMed Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM: Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010, 26: i237-245. 10.1093/bioinformatics/btq182PubMedCentralCrossRefPubMed
21.
go back to reference Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T: The UCSC Cancer Genomics Browser. Nature methods. 2009, 6: 239-240. 10.1038/nmeth0409-239CrossRefPubMed Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T: The UCSC Cancer Genomics Browser. Nature methods. 2009, 6: 239-240. 10.1038/nmeth0409-239CrossRefPubMed
22.
go back to reference Jezequel P, Frenel JS, Campion L, Guerin-Charbonnel C, Gouraud W, Ricolleau G, Campone M:bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the journal of biological databases and curation. 2013, 2013: bas060-CrossRefPubMed Jezequel P, Frenel JS, Campion L, Guerin-Charbonnel C, Gouraud W, Ricolleau G, Campone M:bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the journal of biological databases and curation. 2013, 2013: bas060-CrossRefPubMed
23.
go back to reference Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME: Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PloS one. 2012, 7: e49067- 10.1371/journal.pone.0049067PubMedCentralCrossRefPubMed Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME: Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PloS one. 2012, 7: e49067- 10.1371/journal.pone.0049067PubMedCentralCrossRefPubMed
24.
go back to reference Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: PID: the Pathway Interaction Database. Nucleic acids research. 2009, 37: D674-679. 10.1093/nar/gkn653PubMedCentralCrossRefPubMed Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: PID: the Pathway Interaction Database. Nucleic acids research. 2009, 37: D674-679. 10.1093/nar/gkn653PubMedCentralCrossRefPubMed
25.
go back to reference Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K: Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Molecular cancer research : MCR. 2013, 11: 1269-1278. 10.1158/1541-7786.MCR-13-0212CrossRefPubMed Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K: Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Molecular cancer research : MCR. 2013, 11: 1269-1278. 10.1158/1541-7786.MCR-13-0212CrossRefPubMed
26.
go back to reference Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ: The UCSC Genome Browser database: update 2010. Nucleic acids research. 2010, 38: D613-619.PubMedCentralCrossRefPubMed Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ: The UCSC Genome Browser database: update 2010. Nucleic acids research. 2010, 38: D613-619.PubMedCentralCrossRefPubMed
27.
go back to reference Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature. 2008, 456: 470-476. 10.1038/nature07509PubMedCentralCrossRefPubMed Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature. 2008, 456: 470-476. 10.1038/nature07509PubMedCentralCrossRefPubMed
28.
go back to reference Creighton CJ: The molecular profile of luminal B breast cancer. Biologics: targets & therapy. 2012, 6: 289-297. Creighton CJ: The molecular profile of luminal B breast cancer. Biologics: targets & therapy. 2012, 6: 289-297.
29.
go back to reference Kim HJ, Cui X, Hilsenbeck SG, Lee AV:Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006, 12: 1013s-1018s. 10.1158/1078-0432.CCR-05-2128CrossRef Kim HJ, Cui X, Hilsenbeck SG, Lee AV:Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006, 12: 1013s-1018s. 10.1158/1078-0432.CCR-05-2128CrossRef
30.
go back to reference Lu Z, Ye Y, Jiao D, Qiao J, Cui S: Liu Z: miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology letters. 2012, 4: 1027-1032.PubMedCentralPubMed Lu Z, Ye Y, Jiao D, Qiao J, Cui S: Liu Z: miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology letters. 2012, 4: 1027-1032.PubMedCentralPubMed
31.
go back to reference Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N: FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Developmental cell. 2010, 18: 592-604. 10.1016/j.devcel.2010.03.008PubMedCentralCrossRefPubMed Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N: FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Developmental cell. 2010, 18: 592-604. 10.1016/j.devcel.2010.03.008PubMedCentralCrossRefPubMed
32.
go back to reference Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology : CB. 2004, 14: 1296-1302. 10.1016/j.cub.2004.06.054CrossRefPubMed Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology : CB. 2004, 14: 1296-1302. 10.1016/j.cub.2004.06.054CrossRefPubMed
33.
go back to reference Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA: New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast. 2009, 18 (Suppl 3): S10-17.PubMedCentralCrossRefPubMed Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA: New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast. 2009, 18 (Suppl 3): S10-17.PubMedCentralCrossRefPubMed
34.
go back to reference Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ: MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009, 136: 683-693. 10.1053/j.gastro.2008.10.029CrossRefPubMed Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ: MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009, 136: 683-693. 10.1053/j.gastro.2008.10.029CrossRefPubMed
35.
go back to reference Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30: 1082-1097. 10.1038/onc.2010.487PubMedCentralCrossRefPubMed Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30: 1082-1097. 10.1038/onc.2010.487PubMedCentralCrossRefPubMed
36.
go back to reference Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. The Journal of biological chemistry. 2008, 283: 31079-31086. 10.1074/jbc.M806041200PubMedCentralCrossRefPubMed Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. The Journal of biological chemistry. 2008, 283: 31079-31086. 10.1074/jbc.M806041200PubMedCentralCrossRefPubMed
37.
go back to reference Zhang C, Zhao J, Deng H: 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Molecular and cellular biochemistry. 2013, 379: 201-211. 10.1007/s11010-013-1642-6CrossRefPubMed Zhang C, Zhao J, Deng H: 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Molecular and cellular biochemistry. 2013, 379: 201-211. 10.1007/s11010-013-1642-6CrossRefPubMed
38.
go back to reference Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer research. 2010, 70: 3119-3127. 10.1158/0008-5472.CAN-09-4250CrossRefPubMed Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer research. 2010, 70: 3119-3127. 10.1158/0008-5472.CAN-09-4250CrossRefPubMed
39.
go back to reference Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of biological chemistry. 2010, 285: 17869-17879. 10.1074/jbc.M110.101055PubMedCentralCrossRefPubMed Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of biological chemistry. 2010, 285: 17869-17879. 10.1074/jbc.M110.101055PubMedCentralCrossRefPubMed
40.
go back to reference Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic oncology. 2010, 119: 586-593. 10.1016/j.ygyno.2010.07.021CrossRefPubMed Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic oncology. 2010, 119: 586-593. 10.1016/j.ygyno.2010.07.021CrossRefPubMed
41.
go back to reference Wang J, Yang K, Zhou L, Minhaowu A, Wu Y, Zhu M, Lai X, Chen T, Feng L, Li M, Huang C, Zhong Q, Huang X:MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS pathogens. 2013, 9: e1003697- 10.1371/journal.ppat.1003697PubMedCentralCrossRefPubMed Wang J, Yang K, Zhou L, Minhaowu A, Wu Y, Zhu M, Lai X, Chen T, Feng L, Li M, Huang C, Zhong Q, Huang X:MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS pathogens. 2013, 9: e1003697- 10.1371/journal.ppat.1003697PubMedCentralCrossRefPubMed
42.
go back to reference Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y, Yang BB, Xu H, Xu N, Zhang Y: Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy. 2014, 10: 70-79. 10.4161/auto.26534CrossRefPubMed Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y, Yang BB, Xu H, Xu N, Zhang Y: Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy. 2014, 10: 70-79. 10.4161/auto.26534CrossRefPubMed
43.
go back to reference Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardy PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006, 12: 7159-7164. 10.1158/1078-0432.CCR-06-1426CrossRef Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardy PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006, 12: 7159-7164. 10.1158/1078-0432.CCR-06-1426CrossRef
44.
go back to reference Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW: Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Analytical biochemistry. 2000, 285: 194-204. 10.1006/abio.2000.4753CrossRefPubMed Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW: Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Analytical biochemistry. 2000, 285: 194-204. 10.1006/abio.2000.4753CrossRefPubMed
45.
go back to reference Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington EK: MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. Journal of virology. 2008, 82: 5295-5306. 10.1128/JVI.02380-07PubMedCentralCrossRefPubMed Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington EK: MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. Journal of virology. 2008, 82: 5295-5306. 10.1128/JVI.02380-07PubMedCentralCrossRefPubMed
46.
go back to reference Marsolier J, Pineau S, Medjkane S, Perichon M, Yin Q, Flemington E, Weitzman MD, Weitzman JB: OncomiR addiction is generated by a miR-155 feedback loop in Theileria-transformed leukocytes. PLoS pathogens. 2013, 9: e1003222- 10.1371/journal.ppat.1003222PubMedCentralCrossRefPubMed Marsolier J, Pineau S, Medjkane S, Perichon M, Yin Q, Flemington E, Weitzman MD, Weitzman JB: OncomiR addiction is generated by a miR-155 feedback loop in Theileria-transformed leukocytes. PLoS pathogens. 2013, 9: e1003222- 10.1371/journal.ppat.1003222PubMedCentralCrossRefPubMed
47.
go back to reference Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast cancer research: BCR. 2012, 14: R79- 10.1186/bcr3192PubMedCentralCrossRefPubMed Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast cancer research: BCR. 2012, 14: R79- 10.1186/bcr3192PubMedCentralCrossRefPubMed
48.
go back to reference Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G: Campion L: bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast cancer research and treatment. 2012, 131: 765-775. 10.1007/s10549-011-1457-7CrossRefPubMed Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G: Campion L: bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast cancer research and treatment. 2012, 131: 765-775. 10.1007/s10549-011-1457-7CrossRefPubMed
Metadata
Title
microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity
Authors
Elizabeth C Martin
Lyndsay V Rhodes
Steven Elliott
Adrienne E Krebs
Kenneth P Nephew
Erik K Flemington
Bridgette M Collins-Burow
Matthew E Burow
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-229

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine